446 related articles for article (PubMed ID: 23953074)
21. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
22. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.
Nadeau DA
Postgrad Med; 2010 May; 122(3):7-15. PubMed ID: 20463409
[TBL] [Abstract][Full Text] [Related]
23. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
Nadeau DA
Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
[TBL] [Abstract][Full Text] [Related]
24. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
25. Incretin therapy and its effect on body weight in patients with diabetes.
Lind M
Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Unger J
J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
[TBL] [Abstract][Full Text] [Related]
27. Beyond glycemic control: treating the entire type 2 diabetes disorder.
Brunton S
Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
[TBL] [Abstract][Full Text] [Related]
28. Choosing among the incretin agents and why it matters.
Unger J
J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
[No Abstract] [Full Text] [Related]
29. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
30. Incretin physiology and its role in type 2 diabetes mellitus.
Svec F
J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
[TBL] [Abstract][Full Text] [Related]
31. Incretin-based therapy compared with non-insulin alternatives in elderly patients with type 2 diabetes.
Zhao Q; Marcy TR
Consult Pharm; 2013 Aug; 28(8):515-8. PubMed ID: 23906896
[TBL] [Abstract][Full Text] [Related]
32. Combination pharmacotherapy with incretins: what works best and when?
Over RK; Ratner RE
Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
[TBL] [Abstract][Full Text] [Related]
33. A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes.
Ampudia-Blasco FJ; Benhamou PY; Charpentier G; Consoli A; Diamant M; Gallwitz B; Khunti K; Mathieu C; Ridderstråle M; Seufert J; Tack C; Vilsbøll T; Phan TM; Stoevelaar H
Diabetes Technol Ther; 2015 Mar; 17(3):194-202. PubMed ID: 25347226
[TBL] [Abstract][Full Text] [Related]
34. Incretins and their role in the management of diabetes.
Frias JP; Edelman SV
Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
[TBL] [Abstract][Full Text] [Related]
35. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
36. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
Dedov II; Shestakova MV; Sukhareva OIu
Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
[TBL] [Abstract][Full Text] [Related]
37. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Fabreegas B
Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
[No Abstract] [Full Text] [Related]
38. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
Ross SA; Ballantine J
Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
[TBL] [Abstract][Full Text] [Related]
39. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
40. [New medications for patients with type 2 diabetes].
Meillet L
Soins; 2014 Oct; (789):15-8. PubMed ID: 25518129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]